A Prospective Cohort Study Of Myasthenia Gravis
- Conditions
- Myasthenia Gravis CrisisMyasthenia Gravis
- Interventions
- Device: biomarkers
- Registration Number
- NCT04674605
- Lead Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Brief Summary
The average annual incidence of Myasthenia gravis is up to (8.0-20.0) / 100,000 people. Myasthenia gravis is an acquired autoimmune disease. All skeletal muscles of patients may be involved. When ocular muscles are involved, ptosis, diplopia and other symptoms may occur. When the laryngopharyngeal muscles are involved, the patient may develop dysarthria, dysphagia and other symptoms. However, when the respiratory muscles are involved, patients will have difficulty in breathing, and some patients may develope myasthenia crisis, and artificial assisted respiratory therapy is often needed.
This study is a prospective observational study, in which patients are continuously enrolled, basic information of patients is collected, and biological samples are collected. The purpose of this study is to improve the diagnosis and prognosis of myasthenia gravis patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 200
- Meeting the diagnosis of myasthenia gravis
- Malignant tumor or other serious chronic disease
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description generalized myasthenia gravis biomarkers - ocular myasthenia gravis biomarkers -
- Primary Outcome Measures
Name Time Method Myasthenia gravis foundation of America post intervention status 3 years Complete Stable Remission (CSR) Pharmacologic Remission (PR) Minimal Manifestations (MM) Change in Status: Improved (I) Unchanged (U) Worse (W) Exacerbation (E) Died of MG (D of MG)
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
The First Affiliated Hospital of Chongqing Medical University
🇨🇳Chongqing, YuZhong District, China